Multiple Myeloma News
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Commonly reported AEs of selinexor include nausea, anorexia, fatigue, thrombocytopenia, and hyponatremia.
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
VRd is a frequently used regimen in patients with newly diagnosed MM.
The triplet regimen resulted in an 18% reduction in risk for death.
Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.
A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.